The oral therapy is aimed at adults with chronic spontaneous urticaria (CSU) who do not respond adequately to H1-antihistamines
KEYTRUDA had previously met its primary endpoint of progression-free survival in all patients
The order will cover the manufacturing of bulk vaccine in 2026
The results mark a potential breakthrough for patients living with CIndU, a condition with limited treatment options
This approval represents the seventh FDA-approved companion diagnostic indication for PD-L1 IHC 22C3 pharmDx with KEYTRUDA
Garijo will be the first woman to lead Sanofi in its history
KEYTRUDA QLEX is contraindicated in patients with known hypersensitivity to its components
Plant 1 continues to serve as a core manufacturing hub for oral solid dosage forms
This innovation enhances viral stability, preserves potency, and reduces allergic reactions and antigen crystallisation-related issues
Sofetabart mipitecan is a novel folate receptor alpha (FR?) antibody-drug conjugate (ADC) leveraging proprietary linker technology and an exatecan payload to target tumor cells
Subscribe To Our Newsletter & Stay Updated
